Showing results (71-80 of 77) with videos related to
Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
Molecular Cancer Therapeutics|February 4, 2015
Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatmentsFrank Loganzo, Xingzhi Tan, Matthew Sung, et al.Proceedings of the National Academy of Sciences of the United States of America|January 21, 2014
A general approach to site-specific antibody drug conjugatesFeng Tian, Yingchun Lu, Anthony Manibusan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2015
Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor RegressionsMarc Damelin, Alexander Bankovich, Albert Park, et al.Molecular Cancer Therapeutics|August 5, 2020
PF-06804103, A Site-specific Anti-HER2 Antibody-Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung CancersEdmund I Graziani, Matthew Sung, Dangshe Ma, et al.Science Translational Medicine|January 13, 2017
A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressionsMarc Damelin, Alexander Bankovich, Jeffrey Bernstein, et al.Nature|October 20, 2006
Corneal avascularity is due to soluble VEGF receptor-1Balamurali K Ambati, Miho Nozaki, Nirbhai Singh, et al.Antibodies (Basel, Switzerland)|September 28, 2019
Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of CancerAdam R Root, Wei Cao, Bilian Li, et al.Pageof 8